The lipid triad, or how to reduce residual cardiovascular risk?;La triade lipidique ou comment réduire le risque vasculaire résiduel?

Annales d'Endocrinologie

Volumn 71, Issue 2, 2010, Pages 89-94

  Girard Mauduit, S ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Dyslipidaemia; Fibrates; Laropiprant; Metabolic syndrome; Nicotinic acid; Statins

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TREDAPTIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; DYSLIPIDEMIA; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTRIGLYCERIDEMIA; INTERVENTION STUDY; LIFESTYLE MODIFICATION; LIPID COMPOSITION; METABOLIC SYNDROME X; MONOTHERAPY; PATHOPHYSIOLOGY; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT RESPONSE; VASCULAR DISEASE;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; META-ANALYSIS AS TOPIC; METABOLIC SYNDROME X; OBESITY; PREVALENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 77952947497     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2010.02.001     Document Type: Review

References (39)

1. Misra A., Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008, 93(suppl. 1):S9-30.
2. Sattar N., McConnachie A., Shaper A.G., Blauw G.J., Buckley B.M., de Craen A.J., et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008, 371:1927-1935.
3. Kahn R. Metabolic syndrome - what is the clinical usefulness?. Lancet 2008, 371:1892-1893.
4. Andreelli F., Ziegler O. Comment prendre en charge le syndrome métabolique ?. Ann Endocrinol 2005, 66:36-45.
5. Nesto R.W. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 2005, 5:379-387.
6. Ghandehari H., Kamal-Bahl S., Wong N.D. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004. Am Heart J 2008, 156:112-119.
7. Fruchart J.C., Sacks F., Hermans M.P., Assmann G., Brown W.V., Ceska R., et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102:1K-34K. [suppl.].
8. Assmann G., Schulte H., Cullen P., Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest 2007, 37:925-932.
9. http://www.r3i.org/v1/educationalprogram.asp.
10. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
11. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. J Am Med Assoc 2007, 298:299-308.
12. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. J Am Med Assoc 2007, 298:309-316.
13. Lozano J.V., Pallares V., Cea-Calvo L., Llisterri J.L., Fernandez-Perez C., Mart-Canales J.C., et al. Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. Curr Med Res Opin 2008, 24:659-670.
14. Ballantyne C.M., Olsson A.G., Cook T.J., Mercuri M.F., Pedersen T.R., Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001, 104:3046-3051.
15. Barter P., Antonio M.G., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
16. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724-730.
17. Drexel H. Lipid predictors of cardiovascular events in statin-treated coronary patients with diabetes mellitus. Congress of European Association for the Study of Diabetes (EASD) 2008.
18. Sachdeva A., Cannon C.P., Deedwania P.C., Labresh K.A., Smith S.C., Dai D., et al. Am Heart J 2009, 157:111-117.
19. Lagrost L, Masson D, Chapman J. Lipoprotéines et métabolisme lipidique. In http://www.nsfa.asso.fr/spip.php%3Farticle1069.
20. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., et al. Lipoprotein management in patients with cardiometabolic risk. JACC 2008, 51(15):1512-1524.
21. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
22. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005, 165:1154-1160.
23. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Mantarri M., Heinonen O.P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992, 85:37-45.
24. Scott R., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome, the Fenofibrate Intervention and event Lowering In Diabetes (FIELD) study. Diabetes Care 2009, 32(3):493-498.
25. Barter P. Is high-density lipoprotein the protector of the cardiovascular system?. Eur Heart J Suppl 2004, 6(suppl. A):A19-A22.
26. Hajer G.R., Dallinga-Thie G.M., van Vark-van der Zee L.C., Visseren F.L. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 2009, 202:216-224.
27. Ansquer J.C., Bekaert I., Guy H., Hanefeld M., Simon A. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Am J Cardiovasc Drugs 2009, 9:91-101.
28. Taylor A.J., Villines T.C., Staneck E.J., Devine P.J., Griffen L., Miller M., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
29. Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975, 231:360-381. Coronary Drug Project Research Group.
30. Chapman J. Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. Eur Heart J Suppl 2005, 7(suppl. F):F56-62.
31. McCormack P.L., Keating G.M. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005, 65:2719-2740.
32. Green P.S., Vaisar T., Pennathur S., Kulstad J.J., Moore A.B., Marcovina S., et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 2008, 118:1259-1267.
33. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.C., et al. Simvastatin and niacin, antioxydant vitamins or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
34. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., Grace K.A. Arterial biology for the Investigation of the Treatment Effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
35. Taylor A.J., Lee H.J., Sullenberger L.E. The effect of 24-months of combination statin and extended-release niacin on carotid intima-media thickness. ARBITER 3. Curr Med Res Opin 2006, 22:2243-2250.
36. Brown B.G. Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. Eur Heart J Suppl 2005, 7(suppl. F):F34-F40.
37. Paolini J.F., Mitchel Y.B., Reyes R., Kher U., Lai E., Watson D.J., et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008, 101:625-630.
38. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J.P., Komajda M., et al. Effects of torcetrapid in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
39. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc 2003, 290:2292-2300.